By providing targeted funding and national recognition, the program will bridge critical gaps in the innovation pipeline, helping to translate research and prototypes into scalable, accessible solutions that are strategically aligned with Diabetes Australia's goals.

The Diabetes Australia Grand Innovation Challenge (the Challenge), proudly supported by the Charles Campbell Coghlan OAM Estate, is a national initiative designed to accelerate the development and adoption of breakthrough innovations that address the most pressing needs in diabetes prevention, management, and care.

This Challenge will identify, support, and showcase some of the most promising innovations - ranging from digital and technology health tools, pharmacological therapies, to advanced medical devices - that are ready for real-world impact.

Research must be strategically aligned with Diabetes Australia's goals:

• Cure diabetes - Advance discoveries that bring us closer to a cure.
• Eliminate complications
  Address the medical and psychosocial complications caused by diabetes.
• Prevent diabetes - Understand the causes, tackle risk factors, enhance screening and awareness and interventions to prevent diabetes.
• Reduce financial burden - Develop solutions to ease the financial impact on individuals and the health system.

Who can apply: 

• Startups, entrepreneurs, private sector, researchers and research teams, healthcare providers, and technology developers.
• Innovations must target diabetes prevention, monitoring, treatment, complications management, or cure.
• Applicant must have an ABN
• Product innovation must be at Technology Readiness Level 5-7.

• Email: research@diabetesaustralia.com.au